Side-by-side · Research reference
GLP-1 (7-37)vsLivagen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticHUMAN-REVIEWED16/43 cited
BAnimal-StrongHUMAN-REVIEWED20/32 cited
GLP-1 (7-37)
Incretin Hormone · Native Peptide
Research use only · IV/SC in experimental settings
Livagen
Khavinson Bioregulator · Hepatoprotective Tetrapeptide
Oral or SQ · Tissue-specific to liver
01Mechanism of Action
Parameter
GLP-1 (7-37)
Livagen
Primary target
GLP-1 receptor (class B GPCR)Koole 2015
Hepatocyte protein synthesis machineryBrodskiĭ 2001
Pathway
GLP-1R activation → cAMP production → PKA signaling → insulin secretion (pancreatic β-cells)Lu 2025Koole 2015
Tissue-specific bioregulator → Hepatocyte stimulation → Protein synthesis normalizationBrodskiĭ 2001Khavinson 2001
Downstream effect
Glucose-dependent insulin release, glucagon suppression, delayed gastric emptying, reduced food intakeLu 2025Ding 2017
Age-dependent enzyme normalization, hepatoprotection in fibrosis/hepatitis models, elevated protein synthesis in senescent hepatocytes
Feedback intact?
Yes — physiological secretion and degradation preserved
—
Origin
Endogenous peptide cleaved from proglucagon in intestinal L cells; secreted postprandially
Directed chemical synthesis from amino acid analysis of liver polypeptide preparations (Ventvil)
Antibody development
—
—
02Dosage Protocols
Parameter
GLP-1 (7-37)
Livagen
Clinical use
None — native GLP-1 not used therapeutically
Engineered analogues (semaglutide, liraglutide) used clinically.Friedman 2024
—
Research dosing
Variable — 0.1–10 nmol/kg in animal models
Used as reference standard for analogue comparison.
—
Modified analogues
t½ extended to 13 h (liraglutide), 165 h (semaglutide)
Via DPP-4 resistance + fatty acid acylation.
—
Animal dose (oral)
—
Not specified in abstracts; 2-week administration protocolTimofeeva 2005
Per os administration in rats.
Duration (experimental)
—
2 weeks (enzyme study); up to 24 months (cell culture)Timofeeva 2005Brodskiĭ 2001
Route
—
Oral or subcutaneous
Resists peptidase hydrolysis, enabling oral bioavailability.Timofeeva 2005
Evidence basis
—
Animal models (rats, 1–24 months age); in vitro hepatocyte cultureTimofeeva 2005Brodskiĭ 2001Khavinson 2002
Human data
—
None in provided literature
03Metabolic / Fat Loss Evidence
Parameter
GLP-1 (7-37)
Livagen
Mechanism
GLP-1R activation in hypothalamic satiety centers (arcuate nucleus) reduces food intakeLu 2025
Effect demonstrated with long-acting analogues (liraglutide).Lu 2025
—
Native GLP-1 efficacy
Minimal — rapid degradation prevents sustained appetite suppression
—
Gastric emptying
Delayed in animal models, contributing to satiety
—
Body weight impact
Not observed with native GLP-1 — requires analogue formulations
—
04Side Effects & Safety
Parameter
GLP-1 (7-37)
Livagen
Native GLP-1
Well-tolerated in research settings; no prolonged exposure data
—
Hypoglycemia risk
Low — insulin secretion is glucose-dependent
—
Analogue side effects
Nausea, vomiting, diarrhea (GLP-1R agonists)
Not applicable to native GLP-1 due to non-therapeutic use.
—
GLP-1 resistance
High glucose-induced PKCβ overexpression may reduce GLP-1 responsiveness in endothelial cellsPujadas 2016
—
Reported adverse effects
—
None documented in animal studies
Human safety data
—
No human trials in provided literature
05Administration Protocol
Parameter
GLP-1 (7-37)
Livagen
1. Research use only
Native GLP-1(7-37) is not formulated for therapeutic use. Administered IV or SC in experimental protocols to study GLP-1R pharmacology and as reference standard for analogue development.
Oral administration supported by peptidase resistance. Subcutaneous route used in organotypic culture experiments.Timofeeva 2005Khavinson 2001
2. Storage
Lyophilised peptide stored at -20°C or below. Reconstituted solutions should be prepared fresh and used immediately due to rapid degradation.
No specific timing documented. Two-week protocols used in animal models with daily administration.Timofeeva 2005
3. Clinical alternatives
For therapeutic GLP-1R activation, use FDA-approved long-acting analogues: semaglutide (once weekly), liraglutide (once daily), dulaglutide (once weekly), or exenatide (twice daily or once weekly).
Elderly individuals may exhibit different enzyme normalization patterns than younger cohorts, based on rat age-stratified findings.Timofeeva 2005